Analysis of research and development trends of new drugs

Authors

Ping XU, Shanghai Information Center for Life Sciences, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai 200031, China University of Chinese Academy of Sciences, Beijing 100049, ChinaFollow
Li XU, Shanghai Information Center for Life Sciences, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai 200031, China
Ruo-nan YANG, Shanghai Information Center for Life Sciences, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai 200031, China
Wei LI, Shanghai Information Center for Life Sciences, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai 200031, China
Kaixian CHEN, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, ChinaFollow

Keywords

new drugs, antibody therapeutics, cell therapy, enlightenment, suggestion

Abstract

As an important component in the pharmaceutical innovation, research and development (R&D) of new drugs stands at the forefront of a new round of life science and technology revolution and bioeconomic reform, which is of strategic significance to leading scientific and technological innovation, driving economic development, and improving people’s health and well-being. At present, continuous innovation in cutting-edge technologies, cross-domain integration of disciplines, and digital depth enablement drive active innovation in the field of new drug R&D. Both domestically and internationally, innovative small molecule drugs, antibody drugs, immune cell therapy, gene therapy and nucleic acid drugs are receiving intensive market approvals, providing a wider range of solutions for unmet clinical needs. This study analyzes the development trend of new drug R&D, the global approval situation of new drug R&D, as well as the current situation and trend of new drug R&D in China. It puts forward development enlightenment and suggestions, in order to provide reference for the development of new drug research and development.

First page

821

Last Page

831

Language

Chinese

Publisher

Bulletin of Chinese Academy of Sciences

References

1 Tunyasuvunakool K, Adler J, Wu Z, et al. Highly accurate protein structure prediction for the human proteome. Nature, 2021, 596: 590-596.

2 Mullard A. 2023 FDA approvals. (2024-01-02)[2024-02-20]. https://www.nature.com/articles/d41573-024-00001-x.

3 Qiu Y C, O’Neill N, Maffei B, et al. On-demand cell-autonomous gene therapy for brain circuit disorders. Science, 2022, 378: 523-532.

4 Chen Y F, Hong Z X, Wang J Y, et al. Circuit-specific gene therapy reverses core symptoms in a primate Parkinson’s disease model. Cell, 2023, 186(24): 5394-5410.

5 Squair J W, Milano M, de Coucy A, et al. Recovery of walking after paralysis by regenerating characterized neurons to their natural target region. Science, 2023, 381: 1338-1345.

6 Arbab M, Matuszek Z, Kray K M, et al. Base editing rescue of spinal muscular atrophy in cells and in mice. Science, 2023, 380: eadg6518.

7 McAuley G E, Yiu G, Chang P C, et al. Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing. Cell, 2023, 186: 1398-1416.

8 Lebek S, Chemello F, Caravia X M, et al. Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease. Science, 2023, 379: 179-185.

9 She K, Liu Y, Zhao Q, et al. Dual-AAV split prime editor corrects the mutation and phenotype in mice with inherited retinal degeneration. Signal Transduction and Targeted Therapy, 2023, 8: 57.

10 Everette K A, Newby G A, Levine R M, et al. Ex vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice. Nature Biomedical Engineering, 2023, 7(5): 616-628.

11 Brown K M, Nair J K, Janas M M, et al. Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates. Nature Biotechnology, 2022, 40(10): 1500-1508.

12 Zhang H, Zhang L, Lin A, et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature, 2023, 621: 396-403.

13 Zhi X C, Li Q, Shao L M. Approvals by the China NMPA in 2023. Nature Reviews Drug Discovery, 2024, 23(3): 164-165.

Recommended Citation

XU, Ping; XU, Li; YANG, Ruo-nan; LI, Wei; and CHEN, Kaixian (2024) "Analysis of research and development trends of new drugs," Bulletin of Chinese Academy of Sciences (Chinese Version): Vol. 39 : Iss. 5 , Article 4.
DOI: https://doi.org/10.16418/j.issn.1000-3045.20240312002
Available at: https://bulletinofcas.researchcommons.org/journal/vol39/iss5/4